化疗加艾迪注射液治疗中晚期非小细胞肺癌的临床研究

目的 研究艾迪注射液配合化疗治疗中晚期非小细胞肺癌(NSCLC)的疗效.方法 将123例确诊为中晚期NSCLC的患者随机分为治疗组63例及对照组印例,均采用NP方案化疗,长春瑞滨(NVB)25mg/m2静脉滴注,第1、8天;顺铂(DDP)75mg/m2,分3 d使用并水化.治疗组另加艾迪注射液50ml静脉滴注,第1天至第10天.观察两组近期疗效、不良反应及生活质量.结果 治疗组63例中,CR5例,PR27例,NC15例,PD16例,总有效(CR+PR)率50.8%;对照组60例中,CR3例,PR18例,NC18例,PD21例,总有效率35.0%.主要不良反应为骨髓毒性及胃肠反应,均以治疗组为轻.治疗组生活质量较对照组明显改善,差异均有统计学意义(P＜0.05).结论 艾迪注射液配合NP方案治疗中晚期NSCLC较单纯NP方案可提高疗效,并能减轻不良反应,提高患者的生活质量.

Clinical study of Aidi injection combined with chemotherapy in the treatment of advanced non-small-cell lung cancer

Objective To determine the clinical efficacy of the combination of Aidi injection and chemotherapy in patients of advanced non-small-cell lung cancer (NSCLC). Methods One hundred and twenty three patients with stage ⅢB/Ⅳ NSCLC complying with diagnosis standard were eligible.Those patients were randomly divided into treatment group (63 patients) and control group (60 patients). Both of groups received NP regimens( NVB 25 mg/m2, ivgtt, d1,d8; DDP 25 mg/m2, ivgtt, d1-3, watering). In treatment group,patients received Aidi injection (50 ml, ivgtt, d1-10) combined with NP regimens. Then some indexes were observed, including outcomes in the overall response rates, adverse drug reaction, quality of life. Results In treatment group, outcomes in the overall response rates were 50.8 %, 5 patients were completely remitted(CR),27 patients were partly remitted(PR). In control group, outcomes in the overall response rates were 35.0 %(3 CR, 18 PR). Gastrointestinal reaction and bone marrow depression of treatment group was lower than control group. Quality of life of treatment group was higher than control group. The difference was significant between two groups (P＜0.05). Conclusion This Aidi injection plus chemotherapy combination is effective against NSCLC with mild toxicities and quality of life can be improved.